JP2022551969A5 - - Google Patents
Info
- Publication number
- JP2022551969A5 JP2022551969A5 JP2022522657A JP2022522657A JP2022551969A5 JP 2022551969 A5 JP2022551969 A5 JP 2022551969A5 JP 2022522657 A JP2022522657 A JP 2022522657A JP 2022522657 A JP2022522657 A JP 2022522657A JP 2022551969 A5 JP2022551969 A5 JP 2022551969A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- nos
- cdr2
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915123P | 2019-10-15 | 2019-10-15 | |
| US62/915,123 | 2019-10-15 | ||
| PCT/US2020/055497 WO2021076564A1 (en) | 2019-10-15 | 2020-10-14 | Proteins binding nkg2d, cd16 and flt3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551969A JP2022551969A (ja) | 2022-12-14 |
| JP2022551969A5 true JP2022551969A5 (enExample) | 2023-10-19 |
Family
ID=75538862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522657A Pending JP2022551969A (ja) | 2019-10-15 | 2020-10-14 | Ｎｋｇ２ｄ、ｃｄ１６およびｆｌｔ３に結合するタンパク質 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240117054A1 (enExample) |
| EP (1) | EP4045538A4 (enExample) |
| JP (1) | JP2022551969A (enExample) |
| KR (1) | KR20220083770A (enExample) |
| CN (1) | CN115298217A (enExample) |
| AR (1) | AR120223A1 (enExample) |
| AU (1) | AU2020368163A1 (enExample) |
| BR (1) | BR112022007128A2 (enExample) |
| CA (1) | CA3153858A1 (enExample) |
| CL (2) | CL2022000928A1 (enExample) |
| CO (1) | CO2022004757A2 (enExample) |
| IL (1) | IL292261A (enExample) |
| MX (1) | MX2022004430A (enExample) |
| PE (1) | PE20221316A1 (enExample) |
| TW (1) | TW202128759A (enExample) |
| WO (1) | WO2021076564A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| KR20240049337A (ko) * | 2021-08-24 | 2024-04-16 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Gdf15 융합 단백질 및 이의 용도 |
| WO2023056252A1 (en) * | 2021-09-29 | 2023-04-06 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and baff-r |
| WO2023107956A1 (en) * | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026052582A1 (en) | 2024-09-04 | 2026-03-12 | Red Ridge Bio Ag | Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| JP6441079B2 (ja) * | 2011-12-19 | 2018-12-19 | シンイミューン ゲーエムベーハー | 二重特異性抗体分子 |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| JP2018523471A (ja) * | 2015-07-16 | 2018-08-23 | セレラント セラピューティクス インコーポレイテッド | システイン置換免疫グロブリン |
| EA202090387A1 (ru) * | 2017-07-31 | 2020-05-21 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и flt3 |
| MX2020002036A (es) * | 2017-08-23 | 2020-03-24 | Dragonfly Therapeutics Inc | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. |
| EA202090718A1 (ru) * | 2017-09-14 | 2020-07-01 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) |
| SG11202007579TA (en) * | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) * | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| JP7353576B2 (ja) * | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| JP7539840B2 (ja) * | 2018-02-20 | 2024-08-26 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３を標的とする抗体可変ドメイン及びその使用 |
| US20210221894A1 (en) * | 2018-04-03 | 2021-07-22 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
-
2020
- 2020-10-14 AU AU2020368163A patent/AU2020368163A1/en active Pending
- 2020-10-14 BR BR112022007128A patent/BR112022007128A2/pt unknown
- 2020-10-14 MX MX2022004430A patent/MX2022004430A/es unknown
- 2020-10-14 CN CN202080072319.9A patent/CN115298217A/zh active Pending
- 2020-10-14 JP JP2022522657A patent/JP2022551969A/ja active Pending
- 2020-10-14 US US17/769,160 patent/US20240117054A1/en active Pending
- 2020-10-14 PE PE2022000621A patent/PE20221316A1/es unknown
- 2020-10-14 AR ARP200102840A patent/AR120223A1/es unknown
- 2020-10-14 CA CA3153858A patent/CA3153858A1/en active Pending
- 2020-10-14 TW TW109135528A patent/TW202128759A/zh unknown
- 2020-10-14 EP EP20876627.9A patent/EP4045538A4/en active Pending
- 2020-10-14 KR KR1020227016160A patent/KR20220083770A/ko active Pending
- 2020-10-14 WO PCT/US2020/055497 patent/WO2021076564A1/en not_active Ceased
-
2022
- 2022-04-12 CL CL2022000928A patent/CL2022000928A1/es unknown
- 2022-04-13 IL IL292261A patent/IL292261A/en unknown
- 2022-04-13 CO CONC2022/0004757A patent/CO2022004757A2/es unknown
-
2024
- 2024-12-17 CL CL2024003895A patent/CL2024003895A1/es unknown